The E! Insider Shop editors and writers search the internet to find the best products out there. We interview expert sources, comb through customer reviews, and use our own personal experiences to ...
Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the deal at approximately $3.9 billion, according to Reuters. The agreement is ...
SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and ...
GSK helps SpringWorks to double payday from boosted combo deal as it also reels $225M in new funding
It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part ...
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results